Generalized pustular psoriasis (GPP) is a rare, severe, and potentially life-threatening form of psoriasis marked by widespread inflamed skin and pustules. Flares that can be triggered by factors such as corticosteroid withdrawal, infection, pregnancy, and stress. Although its exact cause is not fully understood, current evidence points to a mix of genetic, environmental, and immune-related drivers. Mutations such as IL36RN underscore the central role of the IL-36 pathway in disease pathogenesis. Treatment has traditionally relied on non-biologic systemic therapies and biologics used more broadly for psoriasis. However, spesolimab—an IL-36 receptor antibody—is now the only treatment specifically approved for GPP, with IV formulations approved for flares in some countries and a subcutaneous formulation approved for flare prevention in the United States and China.

A major recent advance is the International Psoriasis Council’s new global consensus criteria for diagnosing GPP, which aims to standardize recognition of the disease and improve timely treatment. The criteria acknowledge that pustules on the palms and soles can occur during GPP flares without excluding the diagnosis, and they identify erythema as a key feature even when it may be harder to detect in darker skin tones. They also emphasize careful history, physical exam, and biopsy when needed to distinguish GPP from similar conditions such as AGEP and SPD. Direct immunofluorescence appears to have limited value, but the broader framework is meant to help both dermatologists and general practitioners recognize GPP earlier and refer appropriately. Because the consensus was informed by a globally diverse population, including many patients with darker skin tones, it has the potential to improve diagnostic accuracy, equity, and outcomes worldwide.

Reference: Choon SE. New IPC Guidelines on Generalized Pustular Psoriasis. International Psoriasis Council. Published May 2, 2024. Accessed March 26, 2026. https://psoriasiscouncil.org/ipc-news/new-ipc-guidelines-gpp/ 

A new Case Western Reserve University study identified NF-kB c-Rel as a potentially important driver of psoriasis-related inflammation, suggesting it may represent a promising future treatment target. Published in eBioMedicine, the research examined how c-Rel affects dendritic cells and responds to Toll Like Receptor 7 (TLR7) signaling, a pathway involved in innate immunity and inflammation. Researchers found higher levels of c-Rel in skin samples from patients with psoriasis, and in mouse models, the absence of c-Rel reduced inflammation and protected against psoriasis-like skin changes. Together, these findings suggest that c-Rel may play a central role in amplifying the inflammatory response that contributes to the red, scaly lesions seen in psoriasis.

The study also points to a possible connection between viral triggers and worsening psoriatic disease through the TLR7-c-Rel pathway. Because viruses such as HIV, HPV, and hepatitis C can activate TLR7 and have been associated with psoriasis, the researchers believe this signaling pathway may help explain how infection-related immune activity can intensify symptoms in some patients. While the findings are still early and preclinical, the authors say they support further investigation into c-Rel and TLR7 as targets for more precise anti-inflammatory therapies in psoriasis. They also suggest this pathway could have broader relevance in other immune-related conditions, including systemic lupus erythematosus and impaired wound healing in diabetes.

Reference: Editorial Staff. New Case Western Reserve University study identifies key protein’s role in psoriasis. CWRU Newsroom, Case Western Reserve University. Published January 31, 2025. Accessed March 26, 2026. https://case.edu/news/new-case-western-reserve-university-study-identifies-key-proteins-role-psoriasis 

This psoriasis treatment page from the American Academy of Dermatology explains that psoriasis is best diagnosed and managed by a board-certified dermatologist. That evaluation may include examining the skin, scalp, and nails and asking about symptoms, family history, joint pain or stiffness, nail changes, and possible triggers such as illness, medications, or stress. In some cases, a skin biopsy may be performed to help confirm the diagnosis or rule out other conditions that can resemble psoriasis. Accurate diagnosis is especially important because psoriasis can appear differently across skin tones and may involve more than the skin alone, with some patients also developing psoriatic arthritis or other related health concerns. Early recognition can help ensure that patients receive appropriate treatment and monitoring before the disease has a greater impact on quality of life.

Treatment is individualized based on the type, severity, and location of psoriasis, along with how much it affects daily life and the patient’s broader medical history, current medications, and personal treatment goals. Management options may include topical therapies, light therapy, and systemic treatments such as methotrexate, cyclosporine, biologics, apremilast, acitretin, and TYK2 inhibitors. Because psoriasis can change over time and no single therapy works for everyone, patients may need different treatments or combinations of treatments as their disease evolves. Ongoing follow-up is an important part of care, allowing clinicians to adjust therapy, monitor for side effects and comorbidities, screen for psoriatic arthritis, and help patients manage flare-ups and expectations over the long term.

Reference: Ludmann P. Psoriasis: Diagnosis and treatment. American Academy of Dermatology Association. Updated July 16, 2025. Accessed March 26, 2026. https://www.aad.org/public/diseases/psoriasis/treatment/treatment